Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
-
Published:2019-08
Issue:8
Volume:30
Page:1381-1392
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Gomez-Roca C.A.ORCID,
Italiano A.,
Le Tourneau C.,
Cassier P.A.,
Toulmonde M.,
D’Angelo S.P.,
Campone M.,
Weber K.L.,
Loirat D.,
Cannarile M.A.,
Jegg A.-M.,
Ries C.,
Christen R.,
Meneses-Lorente G.,
Jacob W.,
Klaman I.,
Ooi C.-H.,
Watson C.,
Wonde K.,
Reis B.,
Michielin F.,
Rüttinger D.,
Delord J.-P.,
Blay J.-Y.
Funder
GlaxoSmithKline
Taiho Pharmaceutical
Merck
Daiichi-Sankyo
Novartis
Toray Industries
Roche
Genentech
Meso Scale Diagnostics
AstraZeneca
Bayer
Amgen
Bristol-Myers Squibb
F. Hoffmann-La Roche
Subject
Oncology,Hematology
Cited by
136 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献